Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAVR-289
- Development stage
- Preclinical
- Lead developer
- NeoVirTech
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
LAVR-289 is a novel, orally bioavailable acyclic nucleoside phosphonate (ANP) prodrug designed as a broad-spectrum antiviral agent targeting double-stranded DNA (dsDNA) viruses. Derived from the structure of cidofovir, LAVR-289 exhibits significantly lower toxicity and a high selectivity index. It acts by inhibiting viral DNA polymerase, functioning as a fraudulent building block during viral DNA synthesis to block replication firing and prevent the transition from early to late replication phases. LAVR-289 has demonstrated potent nanomolar in vitro and ex vivo efficacy against a wide range of dsDNA viruses, including human cytomegalovirus (HCMV), herpes simplex virus 1 and 2 (HSV-1/2), varicella-zoster virus (VZV), adenoviruses, poxviruses (such as monkeypox virus), and African swine fever virus (ASFV). It is being developed for the prevention and treatment of congenital HCMV infections, as well as opportunistic viral infections in immunocompromised patients.
- Other names
- LAVR 289LAVR289LAVR-289
02
Targets
DNA polymerase family
Beyond the preview
Go deeper on LAVR-289.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LAVR-289.